Plain-English translation of NCT06534723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a 12-month study testing whether — a traditional Chinese herbal medicine in granule form — can help treat mild-to-moderate Alzheimer's disease. Researchers will compare this medication to a placebo (a look-alike with no active ingredient) in about 570 people to see if it improves memory and thinking. Two out of every three participants will receive the active treatment, while one will receive placebo.
Alzheimer's disease causes progressive memory loss and cognitive decline, and current treatment options are limited. This trial explores whether this traditional herbal medicine might offer a new way to slow or improve symptoms in people with mild-to-moderate disease.
You likely qualify if…
You likely don't qualify if…
You would take either the active herbal granules or a placebo twice daily (morning and evening, at least 8 hours apart) for up to 12 months. Neither you nor the researchers will know which treatment you're receiving until the trial ends (this is called 'double-blind'). You'll likely have regular visits to assess your memory, thinking, and overall health throughout the year.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Enrollment target
~570 participants
Started
August 2024
Primary completion
August 2026
Age range
50 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lin song
Fujian Medical University Affiliated Union Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.